Skyline Diagnostics
SkylineDx, Flanders Institute of Biotechnology Partner to Validate Immunotherapy Response Biomarkers
Researchers will assess biomarkers in four clinical trials by mapping the tumor microenvironment using single-cell technology.
SkylineDx, NeraCare Partnering on Proteomic Test for Melanoma
The companies inked a codevelopment and licensing agreement for NeraCare's Immunoprint test for identifying high-risk early-stage melanoma patients.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test
The Belgian molecular diagnostics firm also reported a 70 percent year-over-year increase in commercial cartridge volumes in the first quarter.
SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures for Cancers
SkylineDx said that the firms will work together to develop predictive immunological signatures for BioInvent's lead therapy candidate.